Previous 10 | Next 10 |
Orchard Therapeutics plc (NASDAQ:ORTX) traded today at a new 52-week low of $3.00. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 619,000 shares. Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integr...
Shares of Orchard Therapeutics plc (NASDAQ:ORTX) traded today at $3.20, breaking its 52-week low. Approximately 149,000 shares have changed hands today, as compared to an average 30-day volume of 610,000 shares. Potential upside of 22.8% exists for Orchard Therapeutics plc, based on a cu...
Shares of Orchard Therapeutics plc (NASDAQ:ORTX) traded today at $3.23, breaking its 52-week low. This new low was reached on below average trading volume as 149,000 shares traded hands, while the average 30-day volume is approximately 608,000 shares. Orchard Therapeutics plc (NASDAQ:ORT...
Shares of Orchard Therapeutics plc (NASDAQ:ORTX) traded today at $3.28, breaking its 52-week low. This new low was reached on below average trading volume as 149,000 shares traded hands, while the average 30-day volume is approximately 596,000 shares. Orchard Therapeutics plc has overhea...
Shares of Orchard Therapeutics plc (NASDAQ:ORTX) traded at a new 52-week low today of $3.59. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 581,000 shares. Potential upside of 53.4% exists for Orchard Therapeutics plc, based on a...
Shares of Orchard Therapeutics plc (NASDAQ:ORTX) traded at a new 52-week low today of $3.62. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 563,000 shares. Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fu...
naphtalina/iStock via Getty Images A few collaboration deals in the drug-development space are sparking big gains in Thursday's pre-market action. Spero Therapeutics (SPRO) posted a notable advance, thanks to an investment from drug-making giant Pfizer (PFE). Orchard Therapeutics (ORTX) climb...
Alterity Therapeutics Limited (ATHE) +57% on a new patent by USPTO.Birks Group (BGI) +49% on re-opening of its retail stores across Canada.Wunong Net Technology Company (WNW) +46%.Spero Therapeutics (SPRO) +23% on $40M equity investment from Pfizer.Bridgeline Digital (BLIN) +21...
Orchard Therapeutics (ORTX) and Pharming Group (PHAR) announce a strategic collaboration to research, develop, manufacture and commercialize OTL-105, an investigational ex vivo autologous hematopoietic stem cell ((HSC)) gene therapy for the treatment of hereditary angioedema ((HAE)), a rare d...
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure ...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....